title: Glioblastoma in the elderly.
abstract: There is no generally agreed upon standard of care treatment for elderly patients (age ≥70 years) with glioblastoma (GBM). Treatment options range from supportive care only, radiation therapy (RT) only (most often given in a shortened hypofractionated schedule), temozolomide (TMZ) chemotherapy only, and the combination RT + TMZ, followed by post-RT TMZ as is the current standard of care for younger good performance patients with newly diagnosed GBM.
authors.affiliation: Department of Neurology and Neurological Surgery, University of Washington/Fred Hutchison Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Ave East MS G4940, Box 19023, Seattle, WA, 98109, USA, chambemc@uw.edu.
authors.forename: Marc C
authors.initials: MC
authors.lastname: Chamberlain
mesh_terms: D000368:Aged; D001932:Brain Neoplasms / Q000235:genetics / Q000628:therapy*; D003131:Combined Modality Therapy; D015254:DNA Modification Methylases / Q000235:genetics; D045643:DNA Repair Enzymes / Q000235:genetics; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005909:Glioblastoma / Q000235:genetics / Q000628:therapy*; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics; D000077204:Temozolomide; D025521:Tumor Suppressor Proteins / Q000235:genetics
chemical_list: D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide